June 2, 2022
Life Sciences
  • Pfizer announced that the Food and Drug Administration (FDA) accepted its application for a three-dose COVID-19 vaccine in children aged 6 months to under 5 years old. In February, the FDA asked Pfizer-BioNTech to submit a request for emergency use authorization (EUA) based on the two-dose data but then postponed a meeting of its vaccine advisory committee so the third-dose data could be considered. The committee will meet on June 15 to discuss Moderna and Pfizer’s EUA requests for vaccines for younger children. (Articles here, here, and here)